Heat shock protein 70-the next chaperone to target in the treatment of human acute myelogenous leukemia?

Expert Opinion on Therapeutic Targets

Volumn 18, Issue 8, 2014, Pages 929-944

  Reikvam, Håkon ^a,b   Brenner, Annette K ^a   Nepstad, Ina ^a   Sulen, André ^a   Bruserud, Oystein ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Acute myelogenous leukemia; Heat shock protein 70; Heat shock protein 70 inhibitors; Immunoregulation

Indexed keywords

1 ETHYL 2 [[3 ETHYL 5 (3 METHYLBENZOTHIAZOLIN 2 YLIDENE) 4 OXOTHIAZOLIDIN 2 YLIDENE]METHYL]PYRIDINIUM CHLORIDE; ALVESPIMYCIN; ANTINEOPLASTIC AGENT; BAG 1 PROTEIN; BIOLOGICAL MARKER; CD14 ANTIGEN; CD15 ANTIGEN; CD33 ANTIGEN; CHAPERONE; HEAT SHOCK COGNATE PROTEIN 70; HEAT SHOCK PROTEIN 110; HEAT SHOCK PROTEIN 40; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HEAT SHOCK TRANSCRIPTION FACTOR 1; KNK 437; KRIBB 11; LEUKOCYTE ANTIGEN; MESSENGER RNA; PROTEIN BAX; PUMA PROTEIN; QUERCETIN; TRIPTOLIDE; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VER 155008;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ALLOTRANSPLANTATION; ALPHA HELIX; AMINO TERMINAL SEQUENCE; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; CARBOXY TERMINAL SEQUENCE; CHEMICAL STRUCTURE; CONFORMATIONAL TRANSITION; CROSS PRESENTATION; HUMAN; IMMUNOREGULATION; IN VITRO STUDY; INNATE IMMUNITY; INTRACELLULAR SIGNALING; LEUKEMIA CELL; MOLECULAR INTERACTION; NONHUMAN; OXIDATIVE STRESS; PHASE 1 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REFERENCE DATABASE; REVIEW; ANTAGONISTS AND INHIBITORS; DRUG DESIGN; LEUKEMIA, MYELOID, ACUTE; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROTEIN CONFORMATION; PROTEIN FOLDING;

ANTINEOPLASTIC AGENTS; DRUG DESIGN; HSP70 HEAT-SHOCK PROTEINS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MOLECULAR TARGETED THERAPY; PROTEIN CONFORMATION; PROTEIN FOLDING;

EID: 84904440151     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2014.924925     Document Type: Review

References (136)

1. Welch JS, Ley TJ, Link DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012;150(2):264-78
2. Reikvam H, Nepstad I, Tamburini J. Predicting effects of kinase inhibitor in therapy for myeloid malignancies-the challenges in capturing disease heterogeneity. Expert Opin Investig Drugs 2013;22(11):1365-70
3. Ferrara F, Schiffer CA. Acute myeloid leukaemia in adults. Lancet 2013;381(9865):484-95
4. Patel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012;366(12):1079-89
5. Estey EH. Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012;87(1):89-99
6. Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115(3):453-74
7. Burnett A, Wetzler M, Lowenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol 2011;29(5):487-94
8. Pollyea DA, Kohrt HE, Medeiros BC. Acute myeloid leukaemia in the elderly: A review. Br J Haematol 2011;152(5):524-42
9. Saibil HR. Chaperone machines in action. Curr Opin Struct Biol 2008;18(1):35-42
10. Reikvam H, Ersvaer E, Bruserud O. Heat shock protein 90-a potential target in the treatment of human acute myelogenous leukemia. Curr Cancer Drug Targets 2009;9(6):761-76
11. Reikvam H, Hatfield KJ, Ersvaer E, et al. Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status-consequences and potentials for pharmacological intervention. Br J Haematol 2012;156(4):468-80.
12. Lancet JE, Gojo I, Burton M, et al. Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia. Leukemia 2010;24(4):699-705.
13. Tissieres A, Mitchell HK, Tracy UM. Protein synthesis in salivary glands of Drosophila melanogaster: Relation to chromosome puffs. J Mol Biol 1974;84(3):389-98
14. Schlesinger MJ. Heat shock proteins. J Biol Chem 1990;265(21):12111-14
15. Kampinga HH, Hageman J, Vos MJ, et al. Guidelines for the nomenclature of the human heat shock proteins. Cell Stress Chaperones 2009;14(1):105-11
16. Tavaria M, Gabriele T, Kola I, Anderson RL. A hitchhiker's guide to the human Hsp70 family. Cell Stress Chaperones 1996;1(1):23-8 (Pubitemid 126672886)
17. Kampinga HH, Craig EA. The HSP70 chaperone machinery: J proteins as drivers of functional specificity. Nat Rev Mol Cell Biol 2010;11(8):579-92
18. Mayer MP, Bukau B. Hsp70 chaperones: Cellular functions and molecular mechanism. Cell Mol Life Sci 2005;62(6):670-84
19. Daugaard M, Rohde M, Jaattela M. The heat shock protein 70 family: Highly homologous proteins with overlapping and distinct functions. FEBS Lett 2007;581(19):3702-10 (Pubitemid 47081009)
20. Vos MJ, Hageman J, Carra S, Kampinga HH. Structural and functional diversities between members of the human HSPB, HSPH, HSPA, and DNAJ chaperone families. Biochemistry 2008;47(27):7001-11 (Pubitemid 351956349)
21. Freeman BC, Myers MP, Schumacher R, Morimoto RI. Identification of a regulatory motif in Hsp70 that affects ATPase activity, substrate binding and interaction with HDJ-1. EMBO J 1995;14(10):2281-92
22. Flynn GC, Pohl J, Flocco MT, Rothman JE. Peptide-binding specificity of the molecular chaperone BiP. Nature 1991;353(6346):726-30 (Pubitemid 21912602)
23. Caplan AJ. What is a co-chaperone Cell Stress Chaperones 2003;8(2):105-7
24. Young JC, Hoogenraad NJ, Hartl FU. Molecular chaperones Hsp90 and Hsp70 deliver preproteins to the mitochondrial import receptor Tom70. Cell 2003;112(1):41-50 (Pubitemid 36106417)
25. Hohfeld J, Minami Y, Hartl FU. Hip, a novel cochaperone involved in the eukaryotic Hsc70/Hsp40 reaction cycle. Cell 1995;83(4):589-98
26. Ballinger CA, Connell P, Wu Y, et al. Identification of CHIP, a novel tetratricopeptide repeat-containing protein that interacts with heat shock proteins and negatively regulates chaperone functions. Mol Cell Biol 1999;19(6):4535-45 (Pubitemid 29242026)
27. Ungewickell E, Ungewickell H, Holstein SE, et al. Role of auxilin in uncoating clathrin-coated vesicles. Nature 1995;378(6557):632-5
28. Kabbage M, Dickman MB. The BAG proteins: A ubiquitous family of chaperone regulators. Cell Mol Life Sci 2008;65(9):1390-402
29. Mosser DD, Caron AW, Bourget L, et al. The chaperone function of hsp70 is required for protection against stress-induced apoptosis. Mol Cell Biol 2000;20(19):7146-59
30. Frydman J, Hohfeld J. Chaperones get in touch: The Hip-Hop connection. Trends Biochem Sci 1997;22(3):87-92 (Pubitemid 27107858)
31. Fan AC, Kozlov G, Hoegl A, et al. Interaction between the human mitochondrial import receptors Tom20 and Tom70 in vitro suggests a chaperone displacement mechanism. J Biol Chem 2011;286(37):32208-19
32. Silver JT, Noble EG. Regulation of survival gene hsp70. Cell Stress Chaperones 2012;17(1):1-9
33. Powers MV, Clarke PA, Workman P. Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell 2008;14(3):250-62.
34. Guo F, Rocha K, Bali P, et al. Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin. Cancer Res 2005;65(22):10536-44 (Pubitemid 41743748)
35. Massey AJ, Williamson DS, Browne H, et al. A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells. Cancer Chemother Pharmacol 2010;66(3):535-45
36. Kaiser M, Kuhnl A, Reins J, et al. Antileukemic activity of the HSP70 inhibitor pifithrin-mu in acute leukemia. Blood Cancer J 2011;1(7):e28.
37. Reikvam H, Nepstad I, Sulen A, et al. Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors. Expert Opin Investig Drugs 2013;22(5):551-63.
38. Kerr JF, Wyllie AH, Currie AR. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26(4):239-57
39. Hengartner MO. The biochemistry of apoptosis. Nature 2000;407(6805):770-6
40. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006;25(34):4798-811 (Pubitemid 44187627)
41. Gotoh T, Terada K, Oyadomari S, Mori M. hsp70-DnaJ chaperone pair prevents nitric oxide-and CHOPinduced apoptosis by inhibiting translocation of Bax to mitochondria. Cell Death Differ 2004;11(4):390-402 (Pubitemid 38489417)
42. Gurbuxani S, Schmitt E, Cande C, et al. Heat shock protein 70 binding inhibits the nuclear import of apoptosis-inducing factor. Oncogene 2003;22(43):6669-78 (Pubitemid 37372207)
43. Meriin AB, Yaglom JA, Gabai VL, et al. Protein-damaging stresses activate c-Jun N-terminal kinase via inhibition of its dephosphorylation: A novel pathway controlled by HSP72. Mol Cell Biol 1999;19(4):2547-55 (Pubitemid 29144498)
44. Mosser DD, Caron AW, Bourget L, et al. Role of the human heat shock protein hsp70 in protection against stress-induced apoptosis. Mol Cell Biol 1997;17(9):5317-27 (Pubitemid 27357630)
45. Ravagnan L, Gurbuxani S, Susin SA, et al. Heat-shock protein 70 antagonizes apoptosis-inducing factor. Nat Cell Biol 2001;3(9):839-43 (Pubitemid 32842690)
46. Saleh A, Srinivasula SM, Balkir L, et al. Negative regulation of the Apaf-1 apoptosome by Hsp70. Nat Cell Biol 2000;2(8):476-83
47. Gabai VL, Mabuchi K, Mosser DD, Sherman MY. Hsp72 and stress kinase c-jun N-terminal kinase regulate the bid-dependent pathway in tumor necrosis factor-induced apoptosis. Mol Cell Biol 2002;22(10):3415-24 (Pubitemid 34453981)
48. Park HS, Cho SG, Kim CK, et al. Heat shock protein hsp72 is a negative regulator of apoptosis signal-regulating kinase 1. Mol Cell Biol 2002;22(22):7721-30 (Pubitemid 35217284)
49. Tsuruta F, Sunayama J, Mori Y, et al. JNK promotes Bax translocation to mitochondria through phosphorylation of 14-3-3 proteins. EMBO J 2004;23(8):1889-99 (Pubitemid 38649651)
50. Kim H, Tu HC, Ren D, et al. Stepwise activation of BAX and BAK by tBID, BIM, and PUMA initiates mitochondrial apoptosis. Mol Cell 2009;36(3):487-99
51. Cheng EH, Wei MC, Weiler S, et al. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAXand BAK-mediated mitochondrial apoptosis. Mol Cell 2001;8(3):705-11 (Pubitemid 32946946)
52. Venditti A, Del Poeta G, Maurillo L, et al. Combined analysis of bcl-2 and MDR1 proteins in 256 cases of acute myeloid leukemia. Haematologica 2004;89(8):934-9 (Pubitemid 39049901)
53. Ryningen A, Ersvaer E, Oyan AM, et al. Stress-induced in vitro apoptosis of native human acute myelogenous leukemia (AML) cells shows a wide variation between patients and is associated with low BCL-2:bax ratio and low levels of heat shock protein 70 and 90. Leuk Res 2006;30(12):1531-40 (Pubitemid 44573475)
54. Goldstein JC, Waterhouse NJ, Juin P, et al. The coordinate release of cytochrome c during apoptosis is rapid, complete and kinetically invariant. Nat Cell Biol 2000;2(3):156-62
55. Saleh A, Srinivasula SM, Acharya S, et al. Cytochrome c and dATP-mediated oligomerization of Apaf-1 is a prerequisite for procaspase-9 activation. J Biol Chem 1999;274(25):17941-5
56. Li P, Nijhawan D, Budihardjo I, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997;91(4):479-89 (Pubitemid 27508237)
57. Furukawa Y, Sutheesophon K, Wada T, et al. Methylation silencing of the Apaf-1 gene in acute leukemia. Mol Cancer Res 2005;3(6):325-34 (Pubitemid 40905624)
58. Daugas E, Susin SA, Zamzami N, et al. Mitochondrio-nuclear translocation of AIF in apoptosis and necrosis. FASEB J 2000;14(5):729-39 (Pubitemid 30198571)
59. Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998;94(4):491-501 (Pubitemid 28391865)
60. Chang HY, Nishitoh H, Yang X, et al. Activation of apoptosis signal-regulating kinase 1 (ASK1) by the adapter protein Daxx. Science 1998;281(5384):1860-3 (Pubitemid 28450508)
61. Nishitoh H, Saitoh M, Mochida Y, et al. ASK1 is essential for JNK/SAPK activation by TRAF2. Mol Cell 1998;2(3):389-95 (Pubitemid 128379279)
62. van Eden W, van Herwijnen M, Wagenaar J, et al. Stress proteins are used by the immune system for cognate interactions with anti-inflammatory regulatory T cells. FEBS Lett 2013;587(13):1951-8
63. Schmid D, Munz C. Innate and adaptive immunity through autophagy. Immunity 2007;27(1):11-21 (Pubitemid 47089030)
64. Munz C. Autophagy and antigen presentation. Cell Microbiol 2006;8(6):891-8 (Pubitemid 43670832)
65. Strawbridge AB, Blum JS. Autophagy in MHC class II antigen processing. Curr Opin Immunol 2007;19(1):87-92 (Pubitemid 46073698)
66. Haug M, Schepp CP, Kalbacher H, et al. 70-kDa heat shock proteins: Specific interactions with HLA-DR molecules and their peptide fragments. Eur J Immunol 2007;37(4):1053-63 (Pubitemid 46925341)
67. van Herwijnen MJ, Wieten L, van der Zee R, et al. Regulatory T cells that recognize a ubiquitous stressinducible self-antigen are long-lived suppressors of autoimmune arthritis. Proc Natl Acad Sci USA 2012;109(35):14134-9
68. Mambula SS, Calderwood SK. Heat shock protein 70 is secreted from tumor cells by a nonclassical pathway involving lysosomal endosomes. J Immunol 2006;177(11):7849-57 (Pubitemid 44848243)
69. Srivastava PK. Immunotherapy for human cancer using heat shock proteinpeptide complexes. Curr Oncol Rep 2005;7(2):104-8 (Pubitemid 40485465)
70. Park JE, Facciponte J, Chen X, et al. Chaperoning function of stress protein grp170, a member of the hsp70 superfamily, is responsible for its immunoadjuvant activity. Cancer Res 2006;66(2):1161-8 (Pubitemid 43165986)
71. Jolesch A, Elmer K, Bendz H, et al. Hsp70, a messenger from hyperthermia for the immune system. Eur J Cell Biol 2012;91(1):48-52
72. Manjili MH, Wang XY, Chen X, et al. HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice. J Immunol 2003;171(8):4054-61 (Pubitemid 37238680)
73. Enomoto Y, Bharti A, Khaleque AA, et al. Enhanced immunogenicity of heat shock protein 70 peptide complexes from dendritic cell-tumor fusion cells. J Immunol 2006;177(9):5946-55 (Pubitemid 44628808)
74. Pockley AG, Muthana M, Calderwood SK. The dual immunoregulatory roles of stress proteins. Trends Biochem Sci 2008;33(2):71-9
75. Wang R, Kovalchin JT, Muhlenkamp P, Chandawarkar RY. Exogenous heat shock protein 70 binds macrophage lipid raft microdomain and stimulates phagocytosis, processing, and MHC-II presentation of antigens. Blood 2006;107(4):1636-42 (Pubitemid 43242403)
76. Stangl S, Wortmann A, Guertler U, Multhoff G. Control of metastasized pancreatic carcinomas in SCID/beige mice with human IL-2/TKD-activated NK cells. J Immunol 2006;176(10):6270-6
77. Hirsh MI, Junger WG. Roles of heat shock proteins and gamma delta T cells in inflammation. Am J Respir Cell Mol Biol 2008;39(5):509-13
78. Fredly H, Reikvam H, Gjertsen BT, Bruserud O. Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: Serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment. Am J Hematol 2012;87(4):368-76
79. Thomas X, Campos L, Mounier C, et al. Expression of heat-shock proteins is associated with major adverse prognostic factors in acute myeloid leukemia. Leuk Res 2005;29(9):1049-58 (Pubitemid 40982599)
80. Fredly H, Ersvaer E, Gjertsen BT, Bruserud O. Immunogenic apoptosis in human acute myeloid leukemia (AML): Primary human AML cells expose calreticulin and release heat shock protein (HSP) 70 and HSP90 during apoptosis. Oncol Rep 2011;25(6):1549-56
81. Bogunia-Kubik K, Lange A. HSP70-hom gene polymorphism in allogeneic hematopoietic stem-cell transplant recipients correlates with the development of acute graft-versus-host disease. Transplantation 2005;79(7):815-20 (Pubitemid 40546201)
82. Ersvaer E, Melve GK, Bruserud O. Future perspectives: Should Th17 cells be considered as a possible therapeutic target in acute myeloid leukemia patients receiving allogeneic stem cell transplantation Cancer Immunol Immunother 2011;60(12):1669-81
83. Liseth K, Ersvaer E, Hervig T, Bruserud O. Combination of intensive chemotherapy and anticancer vaccines in the treatment of human malignancies: The hematological experience. J Biomed Biotechnol 2010;2010:692097
84. Schmitt E, Maingret L, Puig PE, et al. Heat shock protein 70 neutralization exerts potent antitumor effects in animal models of colon cancer and melanoma. Cancer Res 2006;66(8):4191-7
85. Schmitt E, Parcellier A, Gurbuxani S, et al. Chemosensitization by a nonapoptogenic heat shock protein 70-binding apoptosis-inducing factor mutant. Cancer Res 2003;63(23):8233-40 (Pubitemid 37549473)
86. Steiner K, Graf M, Hecht K, et al. High HSP70-membrane expression on leukemic cells from patients with acute myeloid leukemia is associated with a worse prognosis. Leukemia 2006;20(11):2076-9 (Pubitemid 44614913)
87. Chant ID, Rose PE, Morris AG. Analysis of heat-shock protein expression in myeloid leukaemia cells by flow cytometry. Br J Haematol 1995;90(1):163-8
88. Yeh CH, Tseng R, Hannah A, et al. Clinical correlation of circulating heat shock protein 70 in acute leukemia. Leuk Res 2010;34(5):605-9.
89. Chant ID, Rose PE, Morris AG. Susceptibility of AML cells to in vitro apoptosis correlates with heat shock protein 70 (hsp 70) expression. Br J Haematol 1996;93(4):898-902
90. Hantschel M, Pfister K, Jordan A, et al. Hsp70 plasma membrane expression on primary tumor biopsy material and bone marrow of leukemic patients. Cell Stress Chaperones 2000;5(5):438-42 (Pubitemid 32057495)
91. Gehrmann M, Schmetzer H, Eissner G, et al. Membrane-bound heat shock protein 70 (Hsp70) in acute myeloid leukemia: A tumor specific recognition structure for the cytolytic activity of autologous NK cells. Haematologica 2003;88(4):474-6 (Pubitemid 36547137)
92. Hromadnikova I, Volchenkov R, Sedlackova L, et al. Expression of heat shock protein 70 and NKG2D ligands in acute myeloid leukemia cell lines. J Recept Signal Transduct Res 2010;30(3):161-9
93. Jensen H, Andresen L, Hansen KA, Skov S. Cell-surface expression of Hsp70 on hematopoietic cancer cells after inhibition of HDAC activity. J Leukoc Biol 2009;86(4):923-32
94. Assimon VA, Gillies AT, Rauch JN, Gestwicki JE. Hsp70 protein complexes as drug targets. Curr Pharm Des 2013;19(3):404-17
95. Powers MV, Jones K, Barillari C, et al. Targeting HSP70: The second potentially druggable heat shock protein and molecular chaperone Cell Cycle 2010;9(8):1542-50
96. Evans CG, Chang L, Gestwicki JE. Heat shock protein 70 (hsp70) as an emerging drug target. J Med Chem 2010;53(12):4585-602
97. Schlecht R, Scholz SR, Dahmen H, et al. Functional analysis of hsp70 inhibitors. PLoS One 2013;8(11):e78443
98. Goloudina AR, Demidov ON, Garrido C. Inhibition of HSP70: A challenging anti-cancer strategy. Cancer Lett 2012;325(2):117-24
99. Budina-Kolomets A, Balaburski GM, Bondar A, et al. Comparison of the activity of three different HSP70 inhibitors on apoptosis, cell cycle arrest, autophagy inhibition, and HSP90 function. Cancer Biol Ther 2014;15(2):194-9
100. Stangl S, Gehrmann M, Riegger J, et al. Targeting membrane heat-shock protein 70 (Hsp70) on tumors by cmHsp70.1 antibody. Proc Natl Acad Sci USA 2011;108(2):733-8
101. Leu JI, Pimkina J, Pandey P, et al. HSP70 inhibition by the small-molecule 2-phenylethynesulfonamide impairs protein clearance pathways in tumor cells. Mol Cancer Res 2011;9(7):936-47
102. Steele AJ, Prentice AG, Hoffbrand AV, et al. 2-Phenylacetylenesulfonamide (PAS) induces p53-independent apoptotic killing of B-chronic lymphocytic leukemia (CLL) cells. Blood 2009;114(6):1217-25
103. Leu JI, Pimkina J, Frank A, et al. A small molecule inhibitor of inducible heat shock protein 70. Mol Cell 2009;36(1):15-27
104. Balaburski GM, Leu JI, Beeharry N, et al. A modified HSP70 inhibitor shows broad activity as an anticancer agent. Mol Cancer Res 2013;11(3):219-29
105. Rousaki A, Miyata Y, Jinwal UK, et al. Allosteric drugs: The interaction of antitumor compound MKT-077 with human Hsp70 chaperones. J Mol Biol 2011;411(3):614-32
106. Koren J III, Miyata Y, Kiray J, et al. Rhodacyanine derivative selectively targets cancer cells and overcomes tamoxifen resistance. PLoS One 2012;7(4):e35566
107. Fewell SW, Day BW, Brodsky JL. Identification of an inhibitor of hsc70-mediated protein translocation and ATP hydrolysis. J Biol Chem 2001;276(2):910-14 (Pubitemid 32096508)
108. Huryn DM, Brodsky JL, Brummond KM, et al. Chemical methodology as a source of smallmolecule checkpoint inhibitors and heat shock protein 70 (Hsp70) modulators. Proc Natl Acad Sci USA 2011;108(17):6757-62
109. Braunstein MJ, Scott SS, Scott CM, et al. Antimyeloma effects of the heat shock protein 70 molecular chaperone inhibitor MAL3-101. J Oncol 2011;2011:232037
110. Cho HJ, Gee HY, Baek KH, et al. A small molecule that binds to an ATPase domain of Hsc70 promotes membrane trafficking of mutant cystic fibrosis transmembrane conductance regulator. J Am Chem Soc 2011;133(50):20267-76
111. Koren J III, Jinwal UK, Jin Y, et al. Facilitating Akt clearance via manipulation of Hsp70 activity and levels. J Biol Chem 2010;285(4):2498-505
112. Propper DJ, Braybrooke JP, Taylor DJ, et al. Phase I trial of the selective mitochondrial toxin MKT077 in chemoresistant solid tumours. Ann Oncol 1999;10(8):923-7 (Pubitemid 29424571)
113. Chatterjee M, Andrulis M, Stuhmer T, et al. The PI3K/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma. Haematologica 2013;98(7):1132-41
114. Cassel JA, Ilyin S, McDonnell ME, Reitz AB. Novel inhibitors of heat shock protein Hsp70-mediated luciferase refolding that bind to DnaJ. Bioorg Med Chem 2012;20(11):3609-14
115. McConnell JR, McAlpine SR. Heat shock proteins 27, 40, and 70 as combinational and dual therapeutic cancer targets. Bioorg Med Chem Lett 2013;23(7):1923-8
116. Yi F, Regan L. A novel class of small molecule inhibitors of Hsp90. ACS Chem Biol 2008;3(10):645-54
117. Gupta UK, Mahanta S, Paul S. In silico design of small peptide-based Hsp90 inhibitor: A novel anticancer agent. Med Hypotheses 2013;81(5):853-61
118. Nagai N, Nakai A, Nagata K. Quercetin suppresses heat shock response by down regulation of HSF1. Biochem Biophys Res Commun 1995;208(3):1099-105
119. Yokota S, Kitahara M, Nagata K. Benzylidene lactam compound, KNK437, a novel inhibitor of acquisition of thermotolerance and heat shock protein induction in human colon carcinoma cells. Cancer Res 2000;60(11):2942-8 (Pubitemid 30395819)
120. Westerheide SD, Kawahara TL, Orton K, Morimoto RI. Triptolide, an inhibitor of the human heat shock response that enhances stress-induced cell death. J Biol Chem 2006;281(14):9616-22 (Pubitemid 43864680)
121. Yoon YJ, Kim JA, Shin KD, et al. KRIBB11 inhibits HSP70 synthesis through inhibition of heat shock factor 1 function by impairing the recruitment of positive transcription elongation factor b to the hsp70 promoter. J Biol Chem 2011;286(3):1737-47
122. Powers MV, Workman P. Inhibitors of the heat shock response: Biology and pharmacology. FEBS Lett 2007;581(19):3758-69 (Pubitemid 47081010)
123. Kaufmann SH, Karp JE, Litzow MR, et al. Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia. Haematologica 2011;96(11):1619-26
124. Al Shaer L, Walsby E, Gilkes A, et al. Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling. Br J Haematol 2008;141(4):483-93 (Pubitemid 351550553)
125. Powers MV, Clarke PA, Workman P. Death by chaperone: HSP90, HSP70 or both Cell Cycle 2009;8(4):518-26
126. Fredly H, Ersvaer E, Kittang AO, et al. The combination of valproic acid, alltrans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia. Clin Epigenetics 2013;5(1):13
127. Fredly H, Gjertsen BT, Bruserud O. Histone deacetylase inhibition in the treatment of acute myeloid leukemia: The effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents. Clin Epigenetics 2013;5(1):12
128. Amadori S, Breccia M, Stasi R. Acute myeloid leukemia in older patients: Conventional and new therapies. Hematol Educ 2013;41-8
129. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010;28(4):562-9
130. Fredly H, Ersvaer E, Stapnes C, et al. The combination of conventional chemotherapy with new targeted therapy in hematologic malignancies: The safety and efficiency of low-dose cytarabine supports its combination with new therapeutic agents in early clinical trials. Curr Cancer Ther Rev 2009;5:243-55
131. Stapnes C, Doskeland AP, Hatfield K, et al. The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells. Br J Haematol 2007;136(6):814-28 (Pubitemid 46348414)
132. Attar EC, Johnson JL, Amrein PC, et al. Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502. J Clin Oncol 2013;31(7):923-9
133. Reikvam H, Tamburini J, Skrede S, et al. Antileukaemic effect of PI3KmTOR inhibitors in acute myeloid leukaemia-gene expression profiles reveal CDC25B expression as determinate of pharmacological effect. Br J Haematol 2014;164(2):200-11
134. Cornelissen JJ, Gratwohl A, Schlenk RF, et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: An integrated-risk adapted approach. Nat Rev Clin Oncol 2012;9(10):579-90
135. Reikvam H, Kittang AO, Melve G, et al. Targeted anti-leukemic therapy as disease-stabilizing treatment for acute myeloid leukemia relapse after allogeneic stem cell transplantation: Will it be possible to combine these strategies with retransplantation or donor lymphocyte infusions Curr Cancer Drug Targets 2013;13(1):30-47
136. Reikvam H, Nepstad I, Bruserud O, Hatfield KJ. Pharmacological targeting of the PI3K/mTOR pathway alters the release of angioregulatory mediators both from primary human acute myeloid leukemia cells and their neighboring stromal cells. Oncotarget 2013;4(6):830-43